LH-025

醋酸来普舒肽

Report date: 2022/06/27 20:00:35
NME

Base Information

Drug NameLH-025
Drug Alias NameLH-025
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDr August Wolff
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen Jymed Technology Co LtdLink Health Group
Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A